Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia

Leukemia Research

Volumn 31, Issue 10, 2007, Pages 1403-1411

  Cheng, Yun Chih ^a   Lin, Hsiupen ^a   Huang, Ming Jer ^b   Chow, Jyh Ming ^a   Lin, Shufan ^a   Liu, H Eugene ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Acute myeloid leukemia; c Myc; Valproic acid

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; MYC PROTEIN; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CELL STRAIN U937; CELL STRUCTURE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; GROWTH DISORDER; HUMAN; HUMAN CELL; LEUKEMOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION; GENES, MYC; HUMANS; LEUKEMIA, MYELOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VALPROIC ACID;

EID: 34547652768     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.03.012     Document Type: Article

References (28)

1. Claus R., and Luebbert M. Epigenetic targets in hematopoietic malignancies. Oncogene 22 (2003) 6489-6496
2. Racanicchi S., Maccherani C., Liberatore C., Billi M., Gelmetti V., Panigada M., et al. Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells. EMBO J 24 (2005) 1232-1242
3. Guidez F., Ivins S., Zhu J., Soderstrom M., Waxman S., and Zelent A. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 91 (1998) 2634-2642
4. Berg T., Guo Y., Abdelkarim M., Fliegauf M., and Lubbert M. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. Leukemia Res (2006)
5. Cimino G., Lo-Coco F., Fenu S., Travaglini L., Finolezzi E., Mancini M., et al. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 66 (2006) 8903-8911
6. Tang R., Faussat A.M., Majdak P., Perrot J.Y., Chaoui D., Legrand O., et al. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 18 (2004) 1246-1251
7. Ten Cate B., Samplonius D.F., Bijma T., de Leij L.F., Helfrich W., and Bremer E. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. Leukemia 21 (2007) 248-252
8. Gurvich N., Tsygankova O.M., Meinkoth J.L., and Klein P.S. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64 (2004) 1079-1086
9. Rocchi P., Tonelli R., Camerin C., Purgato S., Fronza R., Bianucci F., et al. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncol Rep 13 (2005) 1139-1144
10. Trus M.R., Yang L., Suarez Saiz F., Bordeleau L., Jurisica I., and Minden M.D. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. Leukemia 19 (2005) 1161-1168
11. Gartel A.L., and Radhakrishnan S.K. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65 (2005) 3980-3985
12. Mukherjee S., and Conrad S.E. c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. J Biol Chem 280 (2005) 17617-17625
13. Mitchell K.O., and El-Deiry W.S. Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells. Cell Growth Differ 10 (1999) 223-230
14. Huang M.-J., Cheng Y.-C., Liu C.-R., Lin S., and Liu H.E. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol 34 (2006) 1480-1489
15. Sundberg T.B., Ney G.M., Subramanian C., Opipari A.W.J., and Glick G.D. The immunomodulatory benzodiazepine Bz-423 inhibits B-cell proliferation by targeting c-Myc protein for rapid and specific degradation. Cancer Res 66 (2006) 1775-1782
16. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20 (2001) 6969-6978
17. Vervoorts J., Luescher-Firzlaff J., and Luescher B. The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem 281 (2006) 34725-34729
18. Chen C.L., Sung J., Cohen M., Chowdhury W.H., Sachs M.D., Li Y., et al. Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. J Pharmacol Exp Ther 319 (2006) 533-542
19. Hoti N., Chowdhury W., Hsieh J.T., Sachs M.D., Lupold S.E., and Rodriguez R. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Mol Ther 14 (2006) 768-778
20. Li X.N., Shu Q., Su J.M., Perlaky L., Blaney S.M., and Lau C.C. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther 4 (2005) 1912-1922
21. Le-Niculescu H., Bonfoco E., Kasuya Y., Claret F.X., Green D.R., and Karin M. Withdrawal of survival factors results in activation of JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol Cell Biol 19 (1999) 751-763
22. Bug G., Gul H., Schwarz K., Pfeifer H., Kampfmann M., Zheng X., et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res 65 (2005) 2537-2541
23. Michaelis M., Suhan T., Michaelis U.R., Beek K., Rothweiler F., Tausch L., et al. Valproic acid induces extracellular signal-regulated kinase 1/2 activation and inhibits apoptosis in endothelial cells. Cell Growth Differ 13 (2006) 446-453
24. Kuendgen A., Knipp S., Fox F., Strupp C., Hildebrandt B., Steidl C., et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol 84 13 (2005) 61-66
25. Bug G., Ritter M., Wassmann B., Schoch C., Heinzel T., Schwarz K., et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 104 (2005) 2717-2725
26. Garcia-Manero G., Kantarjian H.M., Sanchez-Gonzalez B., Yang H., Rosner G., Verstovsek S., et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 108 (2006) 3271-3279
27. Valentini A., Gravina P., Federici G., and Bernardini S. Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells. Cancer Biol Ther (2007) 6
28. Friedmann I., Atmaca A., Chow K.U., Jager E., and Weidmann E. Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer. J Chemother 18 (2006) 415-420